Skip to main content
main-content
Erschienen in: Annals of Surgical Oncology 3/2021

27.07.2020 | Pancreatic Tumors

Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors

verfasst von: MD, PhD Masayuki Tanaka, MD Max Heckler, MD André L. Mihaljevic, MD Pascal Probst, MD Ulla Klaiber, MD Ulrike Heger, MD Simon Schimmack, MD Markus W. Büchler, MD Thilo Hackert

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

The optimal surgical strategy for pancreatic neuroendocrine tumors (PNETs) is unknown. However, current guidelines recommend a watch-and-wait strategy for small nonfunctional PNETs (NF-PNETs). The aim of this study is to investigate the risk stratification and prognostic significance of lymph node metastasis (LNM) of PNETs to guide decision-making for lymphadenectomy.

Patients and Methods

The MEDLINE and Web of Science databases were systematically searched for studies reporting either risk factors of LNM in resected PNETs or survival of patients with LNM. The weighted average incidence of LNM was calculated according to tumor characteristics. Random-effects metaanalyses were performed, and pooled hazard ratios (HR) and their 95% confidence intervals (CI) were calculated to determine the impact of LNM on overall survival (OS). In subgroup analyses, NF-PNETs were assessed.

Results

From a total of 5883 articles, 98 retrospective studies with 13,374 patients undergoing resection for PNET were included. In all PNETs, the weighted median rates of LNM were 11.5% for small (≤ 2 cm) PNETs and 15.8% for G1 PNETs. In NF-PNETs, the rates were 11.2% for small PNETs and 10.3% for G1 PNETs. LNM of all PNETs (HR 3.87, 95% CI 3.00–4.99, P < 0.001) and NF-PNETs (HR 4.98, 95% CI 2.81–8.83, P < 0.001) was associated with worse OS.

Conclusions

LNM is potentially prevalent even in small and well-differentiated PNETs and is associated with worse prognosis. A watch-and-wait strategy for small NF-PNETs should be reappraised, and oncologic resection with lymphadenectomy can be considered. Prospective and controlled studies are needed in the future.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: advances in diagnosis and management. World J Gastroenterol. 2015;21:9512–25. PubMedPubMedCentralCrossRef Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: advances in diagnosis and management. World J Gastroenterol. 2015;21:9512–25. PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72. PubMedCrossRef Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72. PubMedCrossRef
3.
Zurück zum Zitat Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33. PubMedPubMedCentralCrossRef Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33. PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Jilesen AP, van Eijck CH, in’t Hof KH, van Dieren S, Gouma DJ, van Dijkum EJ. Postoperative complications, in-hospital mortality and 5-year survival after surgical resection for patients with a pancreatic neuroendocrine tumor: a systematic review. World J Surg. 2016;40:729–48. PubMedCrossRef Jilesen AP, van Eijck CH, in’t Hof KH, van Dieren S, Gouma DJ, van Dijkum EJ. Postoperative complications, in-hospital mortality and 5-year survival after surgical resection for patients with a pancreatic neuroendocrine tumor: a systematic review. World J Surg. 2016;40:729–48. PubMedCrossRef
5.
Zurück zum Zitat Liu JB, Baker MS. Surgical management of pancreatic neuroendocrine tumors. Surg Clin N Am. 2016;96:1447–68. PubMedCrossRef Liu JB, Baker MS. Surgical management of pancreatic neuroendocrine tumors. Surg Clin N Am. 2016;96:1447–68. PubMedCrossRef
6.
Zurück zum Zitat Goh BK, Chow PK, Tan YM, et al. Validation of five contemporary prognostication systems for primary pancreatic endocrine neoplasms: results from a single institution experience with 61 surgically treated cases. ANZ J Surg. 2011;81:79–85. PubMedCrossRef Goh BK, Chow PK, Tan YM, et al. Validation of five contemporary prognostication systems for primary pancreatic endocrine neoplasms: results from a single institution experience with 61 surgically treated cases. ANZ J Surg. 2011;81:79–85. PubMedCrossRef
7.
Zurück zum Zitat Kim MJ, Choi DW, Choi SH, et al. Surgical strategies for non-functioning pancreatic neuroendocrine tumours. Br J Surg. 2012;99:1562–8. PubMedCrossRef Kim MJ, Choi DW, Choi SH, et al. Surgical strategies for non-functioning pancreatic neuroendocrine tumours. Br J Surg. 2012;99:1562–8. PubMedCrossRef
8.
Zurück zum Zitat Rosenberg AM, Friedmann P, Del Rivero J, Libutti SK, Laird AM. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors. Surgery. 2016;159:302–9. PubMedCrossRef Rosenberg AM, Friedmann P, Del Rivero J, Libutti SK, Laird AM. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors. Surgery. 2016;159:302–9. PubMedCrossRef
9.
Zurück zum Zitat NCCN: National Comprehensive Cancer Network. NCCN guidelines version 1.2015 neuroendocrine tumors. NCCN: National Comprehensive Cancer Network. NCCN guidelines version 1.2015 neuroendocrine tumors.
10.
Zurück zum Zitat Wong J, Fulp WJ, Strosberg JR, Kvols LK, Centeno BA, Hodul PJ. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. Am J Surg. 2014;208:775–80. PubMedCrossRef Wong J, Fulp WJ, Strosberg JR, Kvols LK, Centeno BA, Hodul PJ. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. Am J Surg. 2014;208:775–80. PubMedCrossRef
11.
Zurück zum Zitat Brunner SM, Weber F, Werner JM, et al. Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification. BMC Surg. 2015;15:49. PubMedPubMedCentralCrossRef Brunner SM, Weber F, Werner JM, et al. Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification. BMC Surg. 2015;15:49. PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490–500. PubMedCrossRef Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490–500. PubMedCrossRef
13.
Zurück zum Zitat Fischer L, Bergmann F, Schimmack S, et al. Outcome of surgery for pancreatic neuroendocrine neoplasms. Br J Surg. 2014;101:1405–12. PubMedCrossRef Fischer L, Bergmann F, Schimmack S, et al. Outcome of surgery for pancreatic neuroendocrine neoplasms. Br J Surg. 2014;101:1405–12. PubMedCrossRef
14.
Zurück zum Zitat Postlewait LM, Ethun CG, Baptiste GG, et al. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. J Surg Oncol. 2016;114:440–5. PubMedCrossRef Postlewait LM, Ethun CG, Baptiste GG, et al. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. J Surg Oncol. 2016;114:440–5. PubMedCrossRef
15.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. PubMedPubMedCentralCrossRef Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Copenhagen: The Cochrane Collaboration; 2011. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Copenhagen: The Cochrane Collaboration; 2011.
17.
Zurück zum Zitat Goossen K, Tenckhoff S, Probst P, et al. Optimal literature search for systematic reviews in surgery. Langenbecks Arch Surg. 2018;403:119–29. PubMedCrossRef Goossen K, Tenckhoff S, Probst P, et al. Optimal literature search for systematic reviews in surgery. Langenbecks Arch Surg. 2018;403:119–29. PubMedCrossRef
18.
Zurück zum Zitat Bosman F, Carneiro F, Hruban RH, Theise ND. Pathology and genetics of tumours of the digestive system. 4th ed. Lyon: IARC Press; 2010. Bosman F, Carneiro F, Hruban RH, Theise ND. Pathology and genetics of tumours of the digestive system. 4th ed. Lyon: IARC Press; 2010.
19.
Zurück zum Zitat Lloyd RV, Osamura R, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: IARC Press; 2017. Lloyd RV, Osamura R, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: IARC Press; 2017.
20.
Zurück zum Zitat Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. PubMedPubMedCentralCrossRef Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158:280–6. PubMedCrossRef Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158:280–6. PubMedCrossRef
22.
Zurück zum Zitat Guo J, Zhao J, Bi X, et al. Should surgery be conducted for small nonfunctioning pancreatic neuroendocrine tumors: a systemic review. Oncotarget. 2017;8:35368–75. PubMedPubMedCentralCrossRef Guo J, Zhao J, Bi X, et al. Should surgery be conducted for small nonfunctioning pancreatic neuroendocrine tumors: a systemic review. Oncotarget. 2017;8:35368–75. PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Yang M, Zhang Y, Zeng L, et al. Prognostic validity of the American Joint Committee on Cancer eighth edition TNM staging system for surgically treated and well-differentiated pancreatic neuroendocrine tumors: a comprehensive analysis of 254 consecutive patients from a large Chinese institution. Pancreas. 2019;48:613–21. Yang M, Zhang Y, Zeng L, et al. Prognostic validity of the American Joint Committee on Cancer eighth edition TNM staging system for surgically treated and well-differentiated pancreatic neuroendocrine tumors: a comprehensive analysis of 254 consecutive patients from a large Chinese institution. Pancreas. 2019;48:613–21.
24.
Zurück zum Zitat Souche R, Coignac A, Dupuy M, et al. Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: a retrospective multicentric analysis of 138 consecutive patients. Clin Res Hepatol Gastroenterol. 2020;44:286–94. PubMedCrossRef Souche R, Coignac A, Dupuy M, et al. Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: a retrospective multicentric analysis of 138 consecutive patients. Clin Res Hepatol Gastroenterol. 2020;44:286–94. PubMedCrossRef
25.
Zurück zum Zitat Sho S, Court CM, Winograd P, et al. A prognostic scoring system for the prediction of metastatic recurrence following curative resection of pancreatic neuroendocrine tumors. J Gastrointest Surg. 2019;23:1392–400. PubMedCrossRef Sho S, Court CM, Winograd P, et al. A prognostic scoring system for the prediction of metastatic recurrence following curative resection of pancreatic neuroendocrine tumors. J Gastrointest Surg. 2019;23:1392–400. PubMedCrossRef
26.
Zurück zum Zitat Primavesi F, Klieser E, Cardini B, et al. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: results from the ASSO pNEN study group. Eur J Surg Oncol. 2019; 45:198–206. PubMedCrossRef Primavesi F, Klieser E, Cardini B, et al. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: results from the ASSO pNEN study group. Eur J Surg Oncol. 2019; 45:198–206. PubMedCrossRef
27.
Zurück zum Zitat Mintziras I, Keck T, Werner J, et al. Indications for resection and perioperative outcomes of surgery for pancreatic neuroendocrine neoplasms in Germany: an analysis of the prospective DGAV StuDoQ|Pancreas registry. Surg Today. 2019;49:1013–21. PubMedCrossRef Mintziras I, Keck T, Werner J, et al. Indications for resection and perioperative outcomes of surgery for pancreatic neuroendocrine neoplasms in Germany: an analysis of the prospective DGAV StuDoQ|Pancreas registry. Surg Today. 2019;49:1013–21. PubMedCrossRef
28.
Zurück zum Zitat Masui T, Sato A, Nakano K, et al. Predictive value of the Ki67 index for lymph node metastasis of small non-functioning pancreatic neuroendocrine neoplasms. Surg Today. 2019;49:593–600. PubMedCrossRef Masui T, Sato A, Nakano K, et al. Predictive value of the Ki67 index for lymph node metastasis of small non-functioning pancreatic neuroendocrine neoplasms. Surg Today. 2019;49:593–600. PubMedCrossRef
29.
Zurück zum Zitat Masui T, Anazawa T, Nagai K, et al. Ki-67 index as a guide to surgical management of small pancreatic neuroendocrine neoplasms for lymph node metastasis. Neuroendocrinology. 2019;108:247. Masui T, Anazawa T, Nagai K, et al. Ki-67 index as a guide to surgical management of small pancreatic neuroendocrine neoplasms for lymph node metastasis. Neuroendocrinology. 2019;108:247.
30.
Zurück zum Zitat Marchegiani G, Landoni L, Andrianello S, et al. Patterns of recurrence after resection for pancreatic neuroendocrine tumors: Who, when, and where? Neuroendocrinology. 2019;108:161–71. PubMedCrossRef Marchegiani G, Landoni L, Andrianello S, et al. Patterns of recurrence after resection for pancreatic neuroendocrine tumors: Who, when, and where? Neuroendocrinology. 2019;108:161–71. PubMedCrossRef
32.
Zurück zum Zitat Liu B, Kudo A, Kinowaki Y, et al. A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms. J Gastroenterol. 2019;54:819–28. PubMedCrossRef Liu B, Kudo A, Kinowaki Y, et al. A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms. J Gastroenterol. 2019;54:819–28. PubMedCrossRef
33.
Zurück zum Zitat Landoni L, Marchegiani G, Pollini T, et al. The evolution of surgical strategies for pancreatic neuroendocrine tumors (Pan-NENs): time-trend and outcome analysis from 587 consecutive resections at a high-volume institution. Ann Surg. 2019;269:725–32. PubMedCrossRef Landoni L, Marchegiani G, Pollini T, et al. The evolution of surgical strategies for pancreatic neuroendocrine tumors (Pan-NENs): time-trend and outcome analysis from 587 consecutive resections at a high-volume institution. Ann Surg. 2019;269:725–32. PubMedCrossRef
34.
Zurück zum Zitat Harimoto N, Hoshino K, Muranushi R, et al. Significance of lymph node metastasis in resectable well-differentiated pancreatic neuroendocrine tumor. Pancreas. 2019;48:943–7. PubMedCrossRef Harimoto N, Hoshino K, Muranushi R, et al. Significance of lymph node metastasis in resectable well-differentiated pancreatic neuroendocrine tumor. Pancreas. 2019;48:943–7. PubMedCrossRef
35.
Zurück zum Zitat Sun H, Zhou J, Liu K, Shen T, Wang X, Wang X. Pancreatic neuroendocrine tumors: MR imaging features preoperatively predict lymph node metastasis. Abdom Radiol (NY). 2018;44:1000–9. CrossRef Sun H, Zhou J, Liu K, Shen T, Wang X, Wang X. Pancreatic neuroendocrine tumors: MR imaging features preoperatively predict lymph node metastasis. Abdom Radiol (NY). 2018;44:1000–9. CrossRef
36.
Zurück zum Zitat Sallinen VJ, Le Large TYS, Tieftrunk E, et al. Prognosis of sporadic resected small (</=2 cm) nonfunctional pancreatic neuroendocrine tumors—a multi-institutional study. HPB (Oxford). 2018;20:251–9. CrossRef Sallinen VJ, Le Large TYS, Tieftrunk E, et al. Prognosis of sporadic resected small (</=2 cm) nonfunctional pancreatic neuroendocrine tumors—a multi-institutional study. HPB (Oxford). 2018;20:251–9. CrossRef
37.
Zurück zum Zitat Partelli S, Javed AA, Andreasi V, et al. The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. Eur J Surg Oncol. 2018;44:778–83. PubMedCrossRef Partelli S, Javed AA, Andreasi V, et al. The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. Eur J Surg Oncol. 2018;44:778–83. PubMedCrossRef
38.
Zurück zum Zitat Paiella S, Marchegiani G, Miotto M, et al. Are cystic pancreatic neuroendocrine tumors an indolent entity results from a single-center surgical series. Neuroendocrinology. 2018;106:234–41. PubMedCrossRef Paiella S, Marchegiani G, Miotto M, et al. Are cystic pancreatic neuroendocrine tumors an indolent entity results from a single-center surgical series. Neuroendocrinology. 2018;106:234–41. PubMedCrossRef
39.
Zurück zum Zitat Nell S, Verkooijen HM, Pieterman CRC, et al. Management of MEN1 related nonfunctioning pancreatic NETs: a shifting paradigm: results from the DutchMEN1 study group. Ann Surg. 2018;267:1155–60. PubMedCrossRef Nell S, Verkooijen HM, Pieterman CRC, et al. Management of MEN1 related nonfunctioning pancreatic NETs: a shifting paradigm: results from the DutchMEN1 study group. Ann Surg. 2018;267:1155–60. PubMedCrossRef
40.
Zurück zum Zitat Nakashima Y, Ohtsuka T, Nakamura S, et al. Clinicopathological characteristics of non-functioning cystic pancreatic neuroendocrine tumors. Pancreatology. 2019;19:50–6. PubMedCrossRef Nakashima Y, Ohtsuka T, Nakamura S, et al. Clinicopathological characteristics of non-functioning cystic pancreatic neuroendocrine tumors. Pancreatology. 2019;19:50–6. PubMedCrossRef
41.
Zurück zum Zitat Mintziras I, Keck T, Werner J, et al. Implementation of current ENETS guidelines for surgery of small (</=2 cm) pancreatic neuroendocrine neoplasms in the German surgical community: an analysis of the prospective DGAV StuDoQ|Pancreas Registry. World J Surg. 2019;43:175–82. PubMedCrossRef Mintziras I, Keck T, Werner J, et al. Implementation of current ENETS guidelines for surgery of small (</=2 cm) pancreatic neuroendocrine neoplasms in the German surgical community: an analysis of the prospective DGAV StuDoQ|Pancreas Registry. World J Surg. 2019;43:175–82. PubMedCrossRef
42.
Zurück zum Zitat Masui T, Sato A, Nakano K, et al. Comparison of recurrence between pancreatic and duodenal neuroendocrine neoplasms after curative resection: a single-institution analysis. Ann Surg Oncol. 2018;25:528–34. PubMedCrossRef Masui T, Sato A, Nakano K, et al. Comparison of recurrence between pancreatic and duodenal neuroendocrine neoplasms after curative resection: a single-institution analysis. Ann Surg Oncol. 2018;25:528–34. PubMedCrossRef
43.
Zurück zum Zitat Malpaga A, Miotto M, Elio G, et al. Prognostic value of lymph node status and extent of lymphadenectomy in non functioning pancreatic neuroendocrine tumors: outcome analysis from 378 consecutive resections in a high-volume institution. Neuroendocrinology. 2018;106:272. Malpaga A, Miotto M, Elio G, et al. Prognostic value of lymph node status and extent of lymphadenectomy in non functioning pancreatic neuroendocrine tumors: outcome analysis from 378 consecutive resections in a high-volume institution. Neuroendocrinology. 2018;106:272.
44.
Zurück zum Zitat Lopez-Aguiar AG, Ethun CG, Postlewait LM, et al. Redefining the Ki-67 index stratification for low-grade pancreatic neuroendocrine tumors: improving its prognostic value for recurrence of disease. Ann Surg Oncol. 2018;25:290–8. PubMedCrossRef Lopez-Aguiar AG, Ethun CG, Postlewait LM, et al. Redefining the Ki-67 index stratification for low-grade pancreatic neuroendocrine tumors: improving its prognostic value for recurrence of disease. Ann Surg Oncol. 2018;25:290–8. PubMedCrossRef
45.
Zurück zum Zitat Han X, Xu X, Ma H, et al. Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology. Endocr Connect. 2018;7:355–63. PubMedPubMedCentralCrossRef Han X, Xu X, Ma H, et al. Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology. Endocr Connect. 2018;7:355–63. PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Genc CG, Jilesen AP, Partelli S, et al. A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann Surg. 2018;267:1148–54. PubMedCrossRef Genc CG, Jilesen AP, Partelli S, et al. A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann Surg. 2018;267:1148–54. PubMedCrossRef
47.
Zurück zum Zitat Gao H, Liu L, Wang W, et al. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. Cancer Lett. 2018;412:188–93. PubMedCrossRef Gao H, Liu L, Wang W, et al. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. Cancer Lett. 2018;412:188–93. PubMedCrossRef
48.
Zurück zum Zitat Deng BY, Liu F, Yin SN, Chen AP, Xu L, Li B. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification. Clin Res Hepatol Gastroenterol. 2018;42:261–8. PubMedCrossRef Deng BY, Liu F, Yin SN, Chen AP, Xu L, Li B. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification. Clin Res Hepatol Gastroenterol. 2018;42:261–8. PubMedCrossRef
49.
Zurück zum Zitat Chiloiro S, Lanza F, Bianchi A, et al. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study. Endocrine. 2018;60:362–7. PubMedCrossRef Chiloiro S, Lanza F, Bianchi A, et al. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study. Endocrine. 2018;60:362–7. PubMedCrossRef
50.
Zurück zum Zitat Bu J, Youn S, Kwon W, et al. Prognostic factors of non-functioning pancreatic neuroendocrine tumor revisited: the value of WHO 2010 classification. Ann Hepatobiliary Pancreat Surg. 2018;22:66–74. PubMedPubMedCentralCrossRef Bu J, Youn S, Kwon W, et al. Prognostic factors of non-functioning pancreatic neuroendocrine tumor revisited: the value of WHO 2010 classification. Ann Hepatobiliary Pancreat Surg. 2018;22:66–74. PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Bosch F, Hofmann K, Coenen M, et al. Surgical treatment of pNET—experience of a “high-volume” center. Surg Oncol. 2018;27:409–14. PubMedCrossRef Bosch F, Hofmann K, Coenen M, et al. Surgical treatment of pNET—experience of a “high-volume” center. Surg Oncol. 2018;27:409–14. PubMedCrossRef
52.
Zurück zum Zitat Zhou B, Zhan C, Wu J, Liu J, Zhou J, Zheng S. Prognostic significance of preoperative gamma-glutamyltransferase to lymphocyte ratio index in nonfunctional pancreatic neuroendocrine tumors after curative resection. Sci Rep. 2017;7:13372. PubMedPubMedCentralCrossRef Zhou B, Zhan C, Wu J, Liu J, Zhou J, Zheng S. Prognostic significance of preoperative gamma-glutamyltransferase to lymphocyte ratio index in nonfunctional pancreatic neuroendocrine tumors after curative resection. Sci Rep. 2017;7:13372. PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Zhou B, Duan J, Yan S, Zhou J, Zheng S. Prognostic factors of long-term outcome in surgically resectable pancreatic neuroendocrine tumors: a 12-year experience from a single center. Oncol Lett. 2017;13:1157–64. PubMedPubMedCentralCrossRef Zhou B, Duan J, Yan S, Zhou J, Zheng S. Prognostic factors of long-term outcome in surgically resectable pancreatic neuroendocrine tumors: a 12-year experience from a single center. Oncol Lett. 2017;13:1157–64. PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Zhou B, Deng J, Chen L, Zheng S. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in nonfunctioning pancreatic neuroendocrine tumors. Sci Rep. 2017;7:17506. PubMedPubMedCentralCrossRef Zhou B, Deng J, Chen L, Zheng S. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in nonfunctioning pancreatic neuroendocrine tumors. Sci Rep. 2017;7:17506. PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Yang M, Ke NW, Zhang Y, et al. Functional and non-functional pancreatic neuroendocrine tumours: ENETS or AJCC TNM staging system? Oncotarget. 2017;8:82784–95. PubMedPubMedCentralCrossRef Yang M, Ke NW, Zhang Y, et al. Functional and non-functional pancreatic neuroendocrine tumours: ENETS or AJCC TNM staging system? Oncotarget. 2017;8:82784–95. PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Yamaguchi H, Kimura Y, Imamura M, et al. Oncological features and outcomes of curatively resected non-functional pancreatic neuroendocrine tumor: single institute experiences. J Pancreas. 2017;18:380–6. Yamaguchi H, Kimura Y, Imamura M, et al. Oncological features and outcomes of curatively resected non-functional pancreatic neuroendocrine tumor: single institute experiences. J Pancreas. 2017;18:380–6.
57.
Zurück zum Zitat Tonelli F, Giudici F, Nesi G, Batignani G, Brandi ML. Operation for insulinomas in multiple endocrine neoplasia type 1: when pancreatoduodenectomy is appropriate. Surgery. 2017;161:727–34. PubMedCrossRef Tonelli F, Giudici F, Nesi G, Batignani G, Brandi ML. Operation for insulinomas in multiple endocrine neoplasia type 1: when pancreatoduodenectomy is appropriate. Surgery. 2017;161:727–34. PubMedCrossRef
58.
Zurück zum Zitat Taki K, Hashimoto D, Nakagawa S, et al. Significance of lymph node metastasis in pancreatic neuroendocrine tumor. Surg Today .2017;47:1104–10. PubMedCrossRef Taki K, Hashimoto D, Nakagawa S, et al. Significance of lymph node metastasis in pancreatic neuroendocrine tumor. Surg Today .2017;47:1104–10. PubMedCrossRef
59.
Zurück zum Zitat Ricci C, Taffurelli G, Campana D, et al. Is surgery the best treatment for sporadic small (</=2 cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience. Pancreatology. 2017;17:471–7. PubMedCrossRef Ricci C, Taffurelli G, Campana D, et al. Is surgery the best treatment for sporadic small (</=2 cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience. Pancreatology. 2017;17:471–7. PubMedCrossRef
60.
Zurück zum Zitat Nanno Y, Matsumoto I, Zen Y, et al. Pancreatic duct involvement in well-differentiated neuroendocrine tumors is an independent poor prognostic factor. Ann Surg Oncol. 2017;24:1127–33. PubMedCrossRef Nanno Y, Matsumoto I, Zen Y, et al. Pancreatic duct involvement in well-differentiated neuroendocrine tumors is an independent poor prognostic factor. Ann Surg Oncol. 2017;24:1127–33. PubMedCrossRef
61.
Zurück zum Zitat Mizumoto T, Toyama H, Terai S, et al. Prediction of lymph node metastasis in pancreatic neuroendocrine tumors by contrast enhancement characteristics. Pancreatology. 2017;17:956–61. PubMedCrossRef Mizumoto T, Toyama H, Terai S, et al. Prediction of lymph node metastasis in pancreatic neuroendocrine tumors by contrast enhancement characteristics. Pancreatology. 2017;17:956–61. PubMedCrossRef
62.
Zurück zum Zitat Michelakos T, Marchegiani G, Fernandez-Del Castillo C, et al. Size of pancreatic neuroendocrine tumors correlates with risk of lymph node metastasis. Gastroenterology. 2017;152:S1250. Michelakos T, Marchegiani G, Fernandez-Del Castillo C, et al. Size of pancreatic neuroendocrine tumors correlates with risk of lymph node metastasis. Gastroenterology. 2017;152:S1250.
63.
Zurück zum Zitat Jin K, Luo G, Xu J, et al. Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: a single-center experience in China. Oncol Lett. 2017;13:3163–8. PubMedPubMedCentralCrossRef Jin K, Luo G, Xu J, et al. Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: a single-center experience in China. Oncol Lett. 2017;13:3163–8. PubMedPubMedCentralCrossRef
64.
Zurück zum Zitat Cingarlini S, Ortolani S, Salgarello M, et al. Role of combined 68 Ga-DOTATOC and 18F-FDG positron emission tomography/computed tomography in the diagnostic workup of pancreas neuroendocrine tumors: implications for managing surgical decisions. Pancreas. 2017;46:42–7. PubMedCrossRef Cingarlini S, Ortolani S, Salgarello M, et al. Role of combined 68 Ga-DOTATOC and 18F-FDG positron emission tomography/computed tomography in the diagnostic workup of pancreas neuroendocrine tumors: implications for managing surgical decisions. Pancreas. 2017;46:42–7. PubMedCrossRef
65.
Zurück zum Zitat Choi SH, Kim HJ, Kim SY, et al. Computed tomography features predictive of lymph node involvement in patients with a nonfunctioning pancreatic neuroendocrine tumor. Pancreas. 2017;46:1056–63. PubMedCrossRef Choi SH, Kim HJ, Kim SY, et al. Computed tomography features predictive of lymph node involvement in patients with a nonfunctioning pancreatic neuroendocrine tumor. Pancreas. 2017;46:1056–63. PubMedCrossRef
66.
Zurück zum Zitat Song KB, Kim SC, Kim JH, et al. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours. ANZ J Surg. 2016;86:563–7. PubMedCrossRef Song KB, Kim SC, Kim JH, et al. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours. ANZ J Surg. 2016;86:563–7. PubMedCrossRef
67.
Zurück zum Zitat Satoh K, Sadowski SM, Dieckmann W, et al. (18)F-FDG PET/CT volumetric parameters are associated with tumor grade and metastasis in pancreatic neuroendocrine tumors in von Hippel-Lindau disease. Ann Surg Oncol. 2016;23:714–21. PubMedCrossRef Satoh K, Sadowski SM, Dieckmann W, et al. (18)F-FDG PET/CT volumetric parameters are associated with tumor grade and metastasis in pancreatic neuroendocrine tumors in von Hippel-Lindau disease. Ann Surg Oncol. 2016;23:714–21. PubMedCrossRef
68.
Zurück zum Zitat Partelli S, Tamburrino D, Lopez C, et al. Active surveillance versus surgery of nonfunctioning pancreatic neuroendocrine neoplasms </=2 cm in MEN1 patients. Neuroendocrinology. 2016;103:779–86. PubMedCrossRef Partelli S, Tamburrino D, Lopez C, et al. Active surveillance versus surgery of nonfunctioning pancreatic neuroendocrine neoplasms </=2 cm in MEN1 patients. Neuroendocrinology. 2016;103:779–86. PubMedCrossRef
69.
Zurück zum Zitat Nanno Y, Toyama H, Otani K, et al. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence. Pancreatology. 2016;16:882–7. PubMedCrossRef Nanno Y, Toyama H, Otani K, et al. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence. Pancreatology. 2016;16:882–7. PubMedCrossRef
70.
Zurück zum Zitat Kim JH, Eun HW, Kim YJ, Lee JM, Han JK, Choi BI. Pancreatic neuroendocrine tumour (PNET): staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol. 2016;26:1338–47. PubMedCrossRef Kim JH, Eun HW, Kim YJ, Lee JM, Han JK, Choi BI. Pancreatic neuroendocrine tumour (PNET): staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol. 2016;26:1338–47. PubMedCrossRef
71.
Zurück zum Zitat Crippa S, Partelli S, Bassi C, et al. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: morphology matters. Surgery. 2016;159:862–71. PubMedCrossRef Crippa S, Partelli S, Bassi C, et al. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: morphology matters. Surgery. 2016;159:862–71. PubMedCrossRef
72.
Zurück zum Zitat Cloyd JM, Kopecky KE, Norton JA, et al. Neuroendocrine tumors of the pancreas: degree of cystic component predicts prognosis. Surgery. 2016;160:708–13. PubMedCrossRef Cloyd JM, Kopecky KE, Norton JA, et al. Neuroendocrine tumors of the pancreas: degree of cystic component predicts prognosis. Surgery. 2016;160:708–13. PubMedCrossRef
73.
Zurück zum Zitat Yang M, Ke NW, Zeng L, et al. Survival analyses for patients with surgically resected pancreatic neuroendocrine tumors by World Health Organization 2010 grading classifications and American Joint Committee on Cancer 2010 staging systems. Medicine (Baltimore). 2015;94:e2156. CrossRef Yang M, Ke NW, Zeng L, et al. Survival analyses for patients with surgically resected pancreatic neuroendocrine tumors by World Health Organization 2010 grading classifications and American Joint Committee on Cancer 2010 staging systems. Medicine (Baltimore). 2015;94:e2156. CrossRef
74.
Zurück zum Zitat Watley DC, Ly QP, Talmon G, Are C, Sasson AR. Clinical presentation and outcome of nonfunctional pancreatic neuroendocrine tumors in a modern cohort. Am J Surg. 2015;210:1192–5;discussion 5–6. Watley DC, Ly QP, Talmon G, Are C, Sasson AR. Clinical presentation and outcome of nonfunctional pancreatic neuroendocrine tumors in a modern cohort. Am J Surg. 2015;210:1192–5;discussion 5–6.
75.
Zurück zum Zitat Sallinen V, Haglund C, Seppanen H. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter? Surgery. 2015;158:1556–63. PubMedCrossRef Sallinen V, Haglund C, Seppanen H. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter? Surgery. 2015;158:1556–63. PubMedCrossRef
76.
Zurück zum Zitat Lombardi M, De Lio N, Funel N, et al. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET. J Endocrinol Investig. 2015;38:605–13. CrossRef Lombardi M, De Lio N, Funel N, et al. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET. J Endocrinol Investig. 2015;38:605–13. CrossRef
77.
Zurück zum Zitat Kim JY, Kim MS, Kim KS, et al. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors. Am J Surg Pathol. 2015;39:592–601. PubMedCrossRef Kim JY, Kim MS, Kim KS, et al. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors. Am J Surg Pathol. 2015;39:592–601. PubMedCrossRef
78.
Zurück zum Zitat Jiang Y, Jin JB, Zhan Q, Deng XX, Shen BY. Impact and clinical predictors of lymph node metastases in nonfunctional pancreatic neuroendocrine tumors. Chin Med J (Engl). 2015;128:3335–44. CrossRef Jiang Y, Jin JB, Zhan Q, Deng XX, Shen BY. Impact and clinical predictors of lymph node metastases in nonfunctional pancreatic neuroendocrine tumors. Chin Med J (Engl). 2015;128:3335–44. CrossRef
79.
Zurück zum Zitat Basturk O, Yang Z, Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39:683–90. PubMedPubMedCentralCrossRef Basturk O, Yang Z, Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39:683–90. PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Tsutsumi K, Ohtsuka T, Fujino M, et al. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification. J Hepatobiliary Pancreat Sci. 2014;21:418–25. PubMedCrossRef Tsutsumi K, Ohtsuka T, Fujino M, et al. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification. J Hepatobiliary Pancreat Sci. 2014;21:418–25. PubMedCrossRef
81.
Zurück zum Zitat Kishi Y, Shimada K, Nara S, Esaki M, Hiraoka N, Kosuge T. Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size. Ann Surg Oncol. 2014;21:2882–8. PubMedCrossRef Kishi Y, Shimada K, Nara S, Esaki M, Hiraoka N, Kosuge T. Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size. Ann Surg Oncol. 2014;21:2882–8. PubMedCrossRef
82.
Zurück zum Zitat Hashim YM, Trinkaus KM, Linehan DC, et al. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg. 2014;259:197–203. PubMedCrossRef Hashim YM, Trinkaus KM, Linehan DC, et al. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg. 2014;259:197–203. PubMedCrossRef
83.
Zurück zum Zitat Han X, Xu X, Jin D, Wang D, Ji Y, Lou W. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. Pancreas. 2014;43:526–31. PubMedPubMedCentralCrossRef Han X, Xu X, Jin D, Wang D, Ji Y, Lou W. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. Pancreas. 2014;43:526–31. PubMedPubMedCentralCrossRef
84.
Zurück zum Zitat Ellison TA, Wolfgang CL, Shi C, et al. A single institution’s 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg. 2014;259:204–12. PubMedCrossRef Ellison TA, Wolfgang CL, Shi C, et al. A single institution’s 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg. 2014;259:204–12. PubMedCrossRef
85.
Zurück zum Zitat Birnbaum DJ, Gaujoux S, Cherif R, et al. Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis. Surgery. 2014;155:13–21. PubMedCrossRef Birnbaum DJ, Gaujoux S, Cherif R, et al. Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis. Surgery. 2014;155:13–21. PubMedCrossRef
86.
Zurück zum Zitat Toste PA, Kadera BE, Tatishchev SF, et al. Nonfunctional pancreatic neuroendocrine tumors < 2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival. J Gastrointest Surg. 2013;17:2105–13. PubMedCrossRef Toste PA, Kadera BE, Tatishchev SF, et al. Nonfunctional pancreatic neuroendocrine tumors < 2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival. J Gastrointest Surg. 2013;17:2105–13. PubMedCrossRef
87.
Zurück zum Zitat Ricci C, Casadei R, Taffurelli G, et al. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours. Pancreatology. 2013;13:589–93. PubMedCrossRef Ricci C, Casadei R, Taffurelli G, et al. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours. Pancreatology. 2013;13:589–93. PubMedCrossRef
88.
Zurück zum Zitat Partelli S, Gaujoux S, Boninsegna L, et al. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). JAMA Surg. 2013;148:932–9. PubMedCrossRef Partelli S, Gaujoux S, Boninsegna L, et al. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). JAMA Surg. 2013;148:932–9. PubMedCrossRef
89.
Zurück zum Zitat McCall CM, Shi C, Cornish TC, et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. Am J Surg Pathol. 2013;37:1671–7. PubMedPubMedCentralCrossRef McCall CM, Shi C, Cornish TC, et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. Am J Surg Pathol. 2013;37:1671–7. PubMedPubMedCentralCrossRef
90.
Zurück zum Zitat Haugvik SP, Marangos IP, Rosok BI, et al. Long-term outcome of laparoscopic surgery for pancreatic neuroendocrine tumors. World J Surg. 2013;37:582–90. PubMedCrossRef Haugvik SP, Marangos IP, Rosok BI, et al. Long-term outcome of laparoscopic surgery for pancreatic neuroendocrine tumors. World J Surg. 2013;37:582–90. PubMedCrossRef
91.
Zurück zum Zitat Cherenfant J, Stocker SJ, Gage MK, et al. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2013;154:785–91;discussion 91–3. Cherenfant J, Stocker SJ, Gage MK, et al. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2013;154:785–91;discussion 91–3.
92.
Zurück zum Zitat Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36:173–84. PubMedPubMedCentralCrossRef Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36:173–84. PubMedPubMedCentralCrossRef
93.
Zurück zum Zitat Tsutsumi K, Ohtsuka T, Mori Y, et al. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol. 2012;47:678–85. PubMedCrossRef Tsutsumi K, Ohtsuka T, Mori Y, et al. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol. 2012;47:678–85. PubMedCrossRef
94.
Zurück zum Zitat Singhi AD, Chu LC, Tatsas AD, et al. Cystic pancreatic neuroendocrine tumors: a clinicopathologic study. Am J Surg Pathol. 2012;36:1666–73. PubMedCrossRef Singhi AD, Chu LC, Tatsas AD, et al. Cystic pancreatic neuroendocrine tumors: a clinicopathologic study. Am J Surg Pathol. 2012;36:1666–73. PubMedCrossRef
95.
Zurück zum Zitat Rindi G, Falconi M, Klersy C, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104:764–77. PubMedCrossRef Rindi G, Falconi M, Klersy C, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104:764–77. PubMedCrossRef
96.
Zurück zum Zitat Goodell PP, Krasinskas AM, Davison JM, Hartman DJ. Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors. Am J Clin Pathol. 2012;137:576–82. PubMedCrossRef Goodell PP, Krasinskas AM, Davison JM, Hartman DJ. Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors. Am J Clin Pathol. 2012;137:576–82. PubMedCrossRef
97.
Zurück zum Zitat Crippa S, Zerbi A, Boninsegna L, et al. Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections. Arch Surg. 2012;147:261–6. PubMedCrossRef Crippa S, Zerbi A, Boninsegna L, et al. Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections. Arch Surg. 2012;147:261–6. PubMedCrossRef
98.
Zurück zum Zitat Bartsch DK, Waldmann J, Fendrich V, et al. Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. Br J Surg. 2012;99:1234–40. PubMedCrossRef Bartsch DK, Waldmann J, Fendrich V, et al. Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. Br J Surg. 2012;99:1234–40. PubMedCrossRef
99.
Zurück zum Zitat Varma V, Tariciotti L, Coldham C, Taniere P, Buckels JA, Bramhall SR. Preoperative localisation and surgical management of insulinoma: single centre experience. Dig Surg. 2011;28:63–73. PubMedCrossRef Varma V, Tariciotti L, Coldham C, Taniere P, Buckels JA, Bramhall SR. Preoperative localisation and surgical management of insulinoma: single centre experience. Dig Surg. 2011;28:63–73. PubMedCrossRef
100.
Zurück zum Zitat Nakayama S, Ottomo S, Yoshida H, et al. The strategy of the treatment for pancreatic neuroendocrine tumors with liver or lymph node metastases. Ann Oncol. 2011;22:v68-v. Nakayama S, Ottomo S, Yoshida H, et al. The strategy of the treatment for pancreatic neuroendocrine tumors with liver or lymph node metastases. Ann Oncol. 2011;22:v68-v.
101.
Zurück zum Zitat Maschuw K, Fendrich V, Langer P, Volland C, Ramaswamy A, Bartsch DK. Impact of CT-based diagnostic imaging on management and outcome of nonfunctioning pancreatic tumors. Langenbecks Arch Surg. 2011;396:1181–6. PubMedCrossRef Maschuw K, Fendrich V, Langer P, Volland C, Ramaswamy A, Bartsch DK. Impact of CT-based diagnostic imaging on management and outcome of nonfunctioning pancreatic tumors. Langenbecks Arch Surg. 2011;396:1181–6. PubMedCrossRef
102.
Zurück zum Zitat Lopez CL, Waldmann J, Fendrich V, Langer P, Kann PH, Bartsch DK. Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg. 2011;396:1187–96. PubMedCrossRef Lopez CL, Waldmann J, Fendrich V, Langer P, Kann PH, Bartsch DK. Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg. 2011;396:1187–96. PubMedCrossRef
103.
Zurück zum Zitat Haynes AB, Deshpande V, Ingkakul T, et al. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg. 2011;146:534–8. PubMedPubMedCentralCrossRef Haynes AB, Deshpande V, Ingkakul T, et al. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg. 2011;146:534–8. PubMedPubMedCentralCrossRef
104.
Zurück zum Zitat Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery. 2011;150:75–82. PubMedCrossRef Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery. 2011;150:75–82. PubMedCrossRef
105.
Zurück zum Zitat Pomianowska E, Gladhaug IP, Grzyb K, et al. Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems. Scand J Gastroenterol. 2010;45:971–9. PubMedCrossRef Pomianowska E, Gladhaug IP, Grzyb K, et al. Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems. Scand J Gastroenterol. 2010;45:971–9. PubMedCrossRef
106.
Zurück zum Zitat Falconi M, Zerbi A, Crippa S, et al. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol. 2010;17:1621–7. PubMedCrossRef Falconi M, Zerbi A, Crippa S, et al. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol. 2010;17:1621–7. PubMedCrossRef
107.
Zurück zum Zitat Casadei R, Ricci C, Pezzilli R, et al. Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology. 2010;10:33–8. PubMedCrossRef Casadei R, Ricci C, Pezzilli R, et al. Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology. 2010;10:33–8. PubMedCrossRef
108.
Zurück zum Zitat Boninsegna L, Partelli S, D’Innocenzio MM, et al. Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. Neuroendocrinology. 2010;92:246–51. PubMedCrossRef Boninsegna L, Partelli S, D’Innocenzio MM, et al. Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. Neuroendocrinology. 2010;92:246–51. PubMedCrossRef
109.
Zurück zum Zitat Nomura N, Fujii T, Kanazumi N, et al. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg. 2009;16:639–47. PubMedCrossRef Nomura N, Fujii T, Kanazumi N, et al. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg. 2009;16:639–47. PubMedCrossRef
110.
Zurück zum Zitat Casadei R, Ricci C, Pezzilli R, et al. Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series. World J Surg. 2009;33:2458–63. PubMedCrossRef Casadei R, Ricci C, Pezzilli R, et al. Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series. World J Surg. 2009;33:2458–63. PubMedCrossRef
111.
Zurück zum Zitat Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg. 2008;95:627–35. PubMedCrossRef Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg. 2008;95:627–35. PubMedCrossRef
112.
Zurück zum Zitat Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25:5609–15. PubMedCrossRef Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25:5609–15. PubMedCrossRef
113.
Zurück zum Zitat Fendrich V, Langer P, Celik I, et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Sur. 2006;244:845–51;discussion 52–3. Fendrich V, Langer P, Celik I, et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Sur. 2006;244:845–51;discussion 52–3.
114.
Zurück zum Zitat Sarmiento JM, Farnell MB, Que FG, Nagorney DM. Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas: long-term survival analysis. World J Surg. 2002;26:1267–71. PubMedCrossRef Sarmiento JM, Farnell MB, Que FG, Nagorney DM. Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas: long-term survival analysis. World J Surg. 2002;26:1267–71. PubMedCrossRef
115.
Zurück zum Zitat Ligneau B, Lombard-Bohas C, Partensky C, et al. Cystic endocrine tumors of the pancreas: clinical, radiologic, and histopathologic features in 13 cases. Am J Surg Pathol. 2001;25:752–60. PubMedCrossRef Ligneau B, Lombard-Bohas C, Partensky C, et al. Cystic endocrine tumors of the pancreas: clinical, radiologic, and histopathologic features in 13 cases. Am J Surg Pathol. 2001;25:752–60. PubMedCrossRef
116.
Zurück zum Zitat Heymann MF, Joubert M, Nemeth J, et al. Prognostic and immunohistochemical validation of the capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases. Histopathology. 2000;36:421–32. PubMedCrossRef Heymann MF, Joubert M, Nemeth J, et al. Prognostic and immunohistochemical validation of the capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases. Histopathology. 2000;36:421–32. PubMedCrossRef
117.
Zurück zum Zitat Zhou B, Deng JF, Chen LF, Zheng SS. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in nonfunctioning pancreatic neuroendocrine tumors. Sci Rep. 2017;7:17506. PubMedPubMedCentralCrossRef Zhou B, Deng JF, Chen LF, Zheng SS. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in nonfunctioning pancreatic neuroendocrine tumors. Sci Rep. 2017;7:17506. PubMedPubMedCentralCrossRef
118.
Zurück zum Zitat Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103:153–71. PubMedCrossRef Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103:153–71. PubMedCrossRef
119.
Zurück zum Zitat Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39:735–52. PubMedPubMedCentralCrossRef Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39:735–52. PubMedPubMedCentralCrossRef
120.
Zurück zum Zitat Wu L, Sahara K, Tsilimigras DI, et al. Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: a multi-institutional analysis. J Surg Oncol. 2019;120:1080–6. PubMedCrossRef Wu L, Sahara K, Tsilimigras DI, et al. Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: a multi-institutional analysis. J Surg Oncol. 2019;120:1080–6. PubMedCrossRef
121.
Zurück zum Zitat Lopez-Aguiar AG, Zaidi MY, Beal EW, et al. Defining the role of lymphadenectomy for pancreatic neuroendocrine tumors: an eight-institution study of 695 patients from the US Neuroendocrine Tumor Study Group. Ann Surg Oncol. 2019;26:2517–24. PubMedCrossRef Lopez-Aguiar AG, Zaidi MY, Beal EW, et al. Defining the role of lymphadenectomy for pancreatic neuroendocrine tumors: an eight-institution study of 695 patients from the US Neuroendocrine Tumor Study Group. Ann Surg Oncol. 2019;26:2517–24. PubMedCrossRef
122.
Zurück zum Zitat Ausania F, Senra Del Rio P. Lymphadenectomy in pancreatic neuroendocrine neoplasms: Why are we still debating? Pancreatology. 2018;18:855–61. PubMedCrossRef Ausania F, Senra Del Rio P. Lymphadenectomy in pancreatic neuroendocrine neoplasms: Why are we still debating? Pancreatology. 2018;18:855–61. PubMedCrossRef
123.
Zurück zum Zitat Sahara K, Tsilimigras DI, Mehta R, et al. Trends in the number of lymph nodes evaluated among patients with pancreatic neuroendocrine tumors in the United States: a multi-institutional and national database analysis. Ann Surg Oncol. 2020;27:1203–12. PubMedCrossRef Sahara K, Tsilimigras DI, Mehta R, et al. Trends in the number of lymph nodes evaluated among patients with pancreatic neuroendocrine tumors in the United States: a multi-institutional and national database analysis. Ann Surg Oncol. 2020;27:1203–12. PubMedCrossRef
125.
Zurück zum Zitat Benetatos N, Hodson J, Marudanayagam R, et al. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems. Hepatobiliary Pancreat Dis Int. 2018;17:169–75. PubMedCrossRef Benetatos N, Hodson J, Marudanayagam R, et al. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems. Hepatobiliary Pancreat Dis Int. 2018;17:169–75. PubMedCrossRef
126.
Zurück zum Zitat Ausania F, Senra Del Rio P, Gomez-Bravo MA, et al. Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study. Pancreatology. 2019;19:367–71. PubMedCrossRef Ausania F, Senra Del Rio P, Gomez-Bravo MA, et al. Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study. Pancreatology. 2019;19:367–71. PubMedCrossRef
127.
Zurück zum Zitat Hata T, Motoi F, Ishida M, et al. Effect of hospital volume on surgical outcomes after pancreaticoduodenectomy: a systematic review and meta-analysis. Ann Surg. 2016;263:664–72. PubMedCrossRef Hata T, Motoi F, Ishida M, et al. Effect of hospital volume on surgical outcomes after pancreaticoduodenectomy: a systematic review and meta-analysis. Ann Surg. 2016;263:664–72. PubMedCrossRef
128.
Zurück zum Zitat Chivukula SV, Tierney JF, Hertl M, Poirier J, Keutgen XM. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over- or undertreating patients? Surgery. 2020;167:180–6. PubMedCrossRef Chivukula SV, Tierney JF, Hertl M, Poirier J, Keutgen XM. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over- or undertreating patients? Surgery. 2020;167:180–6. PubMedCrossRef
129.
Zurück zum Zitat Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49:1–33. PubMedPubMedCentralCrossRef Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49:1–33. PubMedPubMedCentralCrossRef
130.
Zurück zum Zitat Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO Grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40:1192–202. PubMedPubMedCentralCrossRef Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO Grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40:1192–202. PubMedPubMedCentralCrossRef
131.
Zurück zum Zitat Guilmette JM, Nosé V. Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances. Adv Anat Pathol. 2019;26:13–30. PubMedCrossRef Guilmette JM, Nosé V. Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances. Adv Anat Pathol. 2019;26:13–30. PubMedCrossRef
132.
Zurück zum Zitat Ishida H, Lam AK. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. Crit Rev Oncol. Hematol. 2020;145:102835. PubMedCrossRef Ishida H, Lam AK. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. Crit Rev Oncol. Hematol. 2020;145:102835. PubMedCrossRef
Metadaten
Titel
Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors
verfasst von
MD, PhD Masayuki Tanaka
MD Max Heckler
MD André L. Mihaljevic
MD Pascal Probst
MD Ulla Klaiber
MD Ulrike Heger
MD Simon Schimmack
MD Markus W. Büchler
MD Thilo Hackert
Publikationsdatum
27.07.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08850-7

Weitere Artikel der Ausgabe 3/2021

Annals of Surgical Oncology 3/2021 Zur Ausgabe

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.